JP2023534916A5 - - Google Patents
Info
- Publication number
- JP2023534916A5 JP2023534916A5 JP2022581408A JP2022581408A JP2023534916A5 JP 2023534916 A5 JP2023534916 A5 JP 2023534916A5 JP 2022581408 A JP2022581408 A JP 2022581408A JP 2022581408 A JP2022581408 A JP 2022581408A JP 2023534916 A5 JP2023534916 A5 JP 2023534916A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- subject
- administration
- nmosd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046133P | 2020-06-30 | 2020-06-30 | |
| US63/046,133 | 2020-06-30 | ||
| US202063052093P | 2020-07-15 | 2020-07-15 | |
| US63/052,093 | 2020-07-15 | ||
| US202063071092P | 2020-08-27 | 2020-08-27 | |
| US63/071,092 | 2020-08-27 | ||
| PCT/US2021/039911 WO2022006283A2 (en) | 2020-06-30 | 2021-06-30 | Methods of treating neuromyelitis optica spectrum disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534916A JP2023534916A (ja) | 2023-08-15 |
| JP2023534916A5 true JP2023534916A5 (cg-RX-API-DMAC7.html) | 2024-07-09 |
Family
ID=79321915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022581408A Pending JP2023534916A (ja) | 2020-06-30 | 2021-06-30 | 視神経脊髄炎スペクトラム障害を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230406928A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4172211A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023534916A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230030642A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116234571A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021299307A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026747A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3178954A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299381A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016236A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022006283A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7900888B2 (ja) * | 2020-10-29 | 2026-08-05 | ビエラ バイオ インコーポレイテッド | 自己免疫疾患を治療するための抗cd19抗体の使用 |
| CN117797245A (zh) * | 2023-12-29 | 2024-04-02 | 广州赛莱拉干细胞科技股份有限公司 | 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101977843B1 (ko) * | 2017-02-16 | 2019-05-13 | 국립암센터 | 시신경척수염 및 다발성경화증의 선별을 위한 바이오마커 및 이의 이용 |
| CN110522908A (zh) * | 2018-05-25 | 2019-12-03 | 荣昌生物制药(烟台)有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
| EP3959241A4 (en) * | 2019-04-24 | 2023-01-25 | Viela Bio, Inc. | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE |
| JP7900888B2 (ja) * | 2020-10-29 | 2026-08-05 | ビエラ バイオ インコーポレイテッド | 自己免疫疾患を治療するための抗cd19抗体の使用 |
-
2021
- 2021-06-30 JP JP2022581408A patent/JP2023534916A/ja active Pending
- 2021-06-30 KR KR1020237002980A patent/KR20230030642A/ko active Pending
- 2021-06-30 MX MX2022016236A patent/MX2022016236A/es unknown
- 2021-06-30 CA CA3178954A patent/CA3178954A1/en active Pending
- 2021-06-30 EP EP21834411.7A patent/EP4172211A4/en active Pending
- 2021-06-30 WO PCT/US2021/039911 patent/WO2022006283A2/en not_active Ceased
- 2021-06-30 IL IL299381A patent/IL299381A/en unknown
- 2021-06-30 BR BR112022026747A patent/BR112022026747A2/pt unknown
- 2021-06-30 CN CN202180046409.5A patent/CN116234571A/zh active Pending
- 2021-06-30 AU AU2021299307A patent/AU2021299307A1/en active Pending
-
2022
- 2022-12-28 US US18/147,287 patent/US20230406928A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder | |
| DK2493503T3 (en) | DOSAGE SCHEDULE FOR THE ADMINISTRATION OF A CD19xCD3 bispecific antibody | |
| JP7125932B2 (ja) | 凝固第ix因子および/または活性化凝固第ix因子ならびに凝固第x因子および/または活性化凝固第x因子を認識する二重特異性抗体の使用法 | |
| US9458241B2 (en) | Antibody induced cell membrane wounding | |
| EP3747464B1 (en) | Methods for treating progressive multiple sclerosis using an anti-cd20 antibody | |
| D'Amico et al. | Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives | |
| JP2022033868A5 (cg-RX-API-DMAC7.html) | ||
| JP7541505B2 (ja) | アルツハイマー病の治療及び予防方法 | |
| JP2024112859A5 (cg-RX-API-DMAC7.html) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2018523684A5 (cg-RX-API-DMAC7.html) | ||
| JP2021532126A5 (cg-RX-API-DMAC7.html) | ||
| JP2022121658A (ja) | アミロイドーシスを処置するための組成物 | |
| WO2013171289A1 (en) | Combination of cd37 antibodies with further agents | |
| WO2018015880A1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| JP2025514142A5 (cg-RX-API-DMAC7.html) | ||
| WO2007035857A2 (en) | Treatment of b cell diseases using anti-germline antibody binding agents | |
| JP2021529766A5 (cg-RX-API-DMAC7.html) | ||
| JP2020500161A5 (cg-RX-API-DMAC7.html) | ||
| EP4583852A1 (en) | Combination treatment of scyllo-inositol and vitamin d and/or other vitamins or active ingredients to treat cognitive disorders | |
| JP2023510854A5 (cg-RX-API-DMAC7.html) | ||
| JP2024532438A5 (cg-RX-API-DMAC7.html) | ||
| JP2023531722A5 (cg-RX-API-DMAC7.html) | ||
| CA3158364A1 (en) | Anti-alpha-synuclein monoclonal antibodies, and methods using same | |
| JP2024522620A5 (cg-RX-API-DMAC7.html) |